Taken together, our results demonstrate that Uro A treatment is a well-tolerated therapy that effectively reduces primary tumor growth, inhibits PI3K/AKT/mTOR signaling, suppresses intratumoral fibrosis and curtails inflammatory cytokine production in an aggressive mouse model of PDAC. This evidence concerns the gene AKT1 and neoplasm.